InterMune Lifted to Hold at Jefferies Group (ITMN)
In other InterMune news, EVP Paul D. Arata sold 7,500 shares of the stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $50.00, for a total transaction of $375,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
InterMune (NASDAQ:ITMN) traded up 35.41% during mid-day trading on Monday, hitting $72.85. The stock had a trading volume of 51,516,068 shares. InterMune has a one year low of $10.95 and a one year high of $55.24. The stock’s 50-day moving average is $45.86 and its 200-day moving average is $36.13. The company’s market cap is $7.866 billion.
InterMune (NASDAQ:ITMN) last released its earnings data on Wednesday, August 6th. The company reported ($0.72) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.56) by $0.16. The company had revenue of $35.70 million for the quarter, compared to the consensus estimate of $33.96 million. During the same quarter last year, the company posted ($0.77) earnings per share. InterMune’s revenue was up 141.2% compared to the same quarter last year. Analysts expect that InterMune will post $-2.75 EPS for the current fiscal year.
A number of other firms have also recently commented on ITMN. Analysts at William Blair raised their price target on shares of InterMune from $55.00 to $74.00 in a research note on Monday. Separately, analysts at Stifel Nicolaus downgraded shares of InterMune from a “buy” rating to a “hold” rating in a research note on Monday. They now have a $53.00 price target on the stock, down previously from $53.80. Finally, analysts at Leerink Swann raised their price target on shares of InterMune from $53.00 to $74.00 in a research note on Monday. Six analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. InterMune has a consensus rating of “Buy” and a consensus target price of $54.09.
InterMune, Inc (NASDAQ:ITMN) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.